<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726982</url>
  </required_header>
  <id_info>
    <org_study_id>B3002021000015</org_study_id>
    <nct_id>NCT04726982</nct_id>
  </id_info>
  <brief_title>Optimal Dosage of Acetazolamide for OSA Treatment</brief_title>
  <official_title>Optimal Dosage of Acetazolamide for Obstructive Sleep Apnea Treatment: a Parallel-group, Double-blind, Placebo-controlled, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acetazolamide, a carbonic anhydrase inhibitor, has received some attention as potential&#xD;
      treatment for obstructive sleep apnea (OSA). It produces a metabolic acidosis by excreting&#xD;
      bicarbonate, thereby stimulating baseline ventilation. Evidence suggests that acetazolamide&#xD;
      primarily improves ventilatory control instability (expressed as loop gain), which is an&#xD;
      important contributor to the pathophysiology of OSA.&#xD;
&#xD;
      Few studies have assessed the efficacy of acetazolamide in patients with OSA. Since most of&#xD;
      them had a small sample size and used different therapeutic dosages, clinical applications&#xD;
      are currently limited. Therefore, this study aims to compare the effect of two acetazolamide&#xD;
      dosages on the severity and pathophysiology of OSA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this double-blind, parallel-group, controlled trial, eligible patients will be randomized&#xD;
      into one of the following treatment arms: (1) placebo, (2) 250 mg of acetazolamide, or (3)&#xD;
      500 mg of acetazolamide. After 4 weeks, treatment outcome will be assessed by in-laboratory&#xD;
      polysomnography. Additionally, arterial blood gas analysis and lung function tests will be&#xD;
      performed before and during treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea-hypopnea index (AHI)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in AHI (events/hour) from baseline to follow-up. The AHI is a measure of sleep apnea severity that encompasses the frequency of apneas (cessations in breathing) and hypopneas (reductions in airflow).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathophysiological traits</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes in pathophysiological traits (Vpassive, Vactive, Arousal Threshold, Loop Gain) will be quantified as %Veupnea from polysomnography data using a validated algorithm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent responders</measure>
    <time_frame>4 weeks</time_frame>
    <description>Treatment response will be defined as a reduction in AHI of ≥ 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal oxygen saturation</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in mean and minimal SaO2 (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen desaturation index (ODI)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in ODI (events/hour) from baseline to follow-up. The ODI represents the average number of desaturation episodes (≥ 3%) per hour sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood gas measurements</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in pO2 (mmhg) and pCO2 (mmhg) from baseline to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function parameters</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in flow-volume curve from baseline to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime sleepiness: Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The ESS asks respondents to rate on a 4-point scale (0-3) their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score (the sum of 8 item scores) can range from 0 to 24. The higher the ESS score, the higher that person's sleep propensity in daily life. A score higher than 10 indicates the presence of excessive daytime sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep-related quality of life: Functional Outcome of Sleep Questionnaire (FOSQ-10)</measure>
    <time_frame>6 weeks</time_frame>
    <description>This questionnaire is an abbreviated version of the original 30-item version. The FOSQ-10 consists of 10 items that are distributed among 5 subscales: general productivity (2 items), activity level (3 items), vigilance (3 items), social outcomes (1 item), and intimacy and sexual relationships (1 item). The questionnaire has a 4-point scale. The total score is calculated as the sum of the subscale means and can range from 5 to 20. The minimal important difference ranges from 1.7 to 2.0 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snoring intensity: Visual Analogue Scale (VAS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>A standard 10-point VAS ranging from 0 (no snoring) to 10 (extreme snoring) will be used to evaluate the subjective status of snoring during sleep. Heavy snoring corresponds to a snoring index of at least 7. A decrease of 3 points after treatment is considered significant. To be considered as an important reduction, snoring needs to reduce to an index that is no longer experienced as bothersome (i.e. &lt; 3).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Safety and tolerability of study treatment.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Low dose acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>250 mg once daily</description>
    <arm_group_label>Low dose acetazolamide</arm_group_label>
    <other_name>Diamox</other_name>
    <other_name>ATC code: S01EC01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>500 mg once daily</description>
    <arm_group_label>High dose acetazolamide</arm_group_label>
    <other_name>Diamox</other_name>
    <other_name>ATC code: S01EC01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AHI between 15 and 65 events/hour&#xD;
&#xD;
          -  BMI &lt; 35 kg/m²&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Craniofacial anomalies&#xD;
&#xD;
          -  Central sleep apnea (defined as central AHI &gt; 25% of total AHI)&#xD;
&#xD;
          -  Contra-indications related to acetazolamide treatment&#xD;
&#xD;
               -  Hypersensitivity to sulphonamides or acetazolamide&#xD;
&#xD;
               -  Renal impairment, electrolyte imbalances, and/or adrenocortical insufficiency&#xD;
&#xD;
               -  Clinically significant metabolic, hepatic, and/or hematological disease&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease&#xD;
&#xD;
               -  Closed-angle glaucoma&#xD;
&#xD;
          -  Conditions likely to affect OSA physiology: neuromuscular disease or other major&#xD;
             neurological disorders, heart failure, or any other unstable major medical condition.&#xD;
&#xD;
          -  Intake of drugs that substantially stimulate or depress respiration, including&#xD;
             benzodiazepines, opioids, theophylline, and pseudoephedrine&#xD;
&#xD;
          -  Inadequately treated sleep disorders other than OSA that would confound functional&#xD;
             sleep assessment&#xD;
&#xD;
          -  Inability of the patient to understand and/or comply to the study procedures&#xD;
&#xD;
          -  Active psychiatric disease (psychotic illness, major depression, anxiety attacks,&#xD;
             alcohol or drug abuse)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Vanderveken, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eli Van de Perck, MD</last_name>
    <phone>38214244</phone>
    <phone_ext>+32</phone_ext>
    <email>eli.vandeperck@uza.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Van de Perck, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Vanderveken, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carbonic anhydrase inhibitor</keyword>
  <keyword>Treatment</keyword>
  <keyword>Pharmacotherapy</keyword>
  <keyword>Sleep apnea</keyword>
  <keyword>Loop gain</keyword>
  <keyword>Respiration</keyword>
  <keyword>Ventilatory control instability</keyword>
  <keyword>Acidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

